5 February 2026
From the regulatory newsfeed of the Medicines and Healthcare products Regulatory Agency (MHRA), Arex Advisor has rounded up a selection of highlights from the past month.
MHRA explains how borderline products are classified as medicines
6 January 2026
The MHRA has set out how it determines whether a product falls within the definition of a medicinal product, focusing on so-called borderline cases. The guidance helps developers understand how factors such as presentation, claims, and mode of action influence regulatory classification and applicable requirements under UK medicines law, as assessed by the Medicines and Healthcare products Regulatory Agency. Read more
Full list of medicines authorised in 2025 now available
15 January 2026
The complete lists of medicinal products granted marketing authorisation in 2025 have been published and are now available for review. The datasets allow stakeholders to assess approval activity over the year and track trends across newly authorised medicines. Read more
MHRA to chair Access Consortium in 2026
26 January 2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) will take over the chair of the Access Consortium in 2026. The Consortium brings together regulators from the UK, Australia, Canada, Singapore, and Switzerland to streamline regulatory processes, support innovation, and improve global public health outcomes through closer international collaboration. Read more
How do these changes affect you?
Our experienced specialists are ready to help you navigate the regulatory landscape!